ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Beligas
WAREHOUSE
International Warehouse 3
SUBSTANCE
Anti-Obesity Drug-9604
AOD 9604 is an advanced peptide derived from Growth Hormone, consisting of 191 amino acids. This innovative formulation features the last 15 amino acids (176-191) of the Growth Hormone chain, commonly known as GH Frag 176-191 or AOD 9604.
Renowned as one of the most powerful peptides for weight loss, AOD 9604 not only aids in shedding pounds but also boosts metabolism and promotes fat reduction.
: Pituitary Gland
Stimulated Gland Benefits of AOD 9604Also referred to as Tyr-hGH Frag 176-191, AOD-9604 is recognized for its remarkable fat-burning capabilities without inciting increased appetite. It does not affect blood sugar or promote tissue growth. This peptide facilitates the breakdown and oxidation of fat without engaging the hGH receptor, setting it apart from standard hGH. Comprehensive research involving various species, including rodents, pigs, dogs, and humans, has revealed that AOD-9604 promotes fat release specifically from obese fat cells while minimizing new fat formation and enhancing fat combustion. Notably, it is especially effective in reducing abdominal fat.
When it comes to fat loss, CJC-1295 is another potent peptide that elevates overall GH levels in the body, counteracting age-related weight gain. For those focused on fat loss, it?s advisable to avoid GHRP products (like GHRP-6, GHRP-2, or GHRH), as they may lead to increased hunger and elevated cortisol levels. In contrast, AOD-9604 is designed to keep hunger at bay and maintain balanced cortisol levels.
Research on AOD 9604Originally developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 was crafted as an anti-obesity drug that emulates the fat-burning capabilities of human growth hormone (HGH) without promoting muscle growth.
Recent investigations have not only highlighted the fat loss advantages of AOD 9604 but also its regenerative properties related to growth hormone. Ongoing studies are examining its potential applications in treating osteoarthritis, managing high cholesterol, and supporting bone and cartilage repair.
Results from oral glucose tolerance tests have shown that, unlike hGH, AOD 9604 does not negatively impact carbohydrate metabolism. No anti-AOD 9604 antibodies were detected in any tested subjects, and no serious adverse events related to AOD 9604 consumption were reported in clinical studies.
ConclusionAOD 9604 boasts a robust safety and tolerability profile, comparable to a placebo, and does not produce the negative side effects commonly associated with full-length hGH therapies. With an excellent safety record, AOD 9604 has recently attained Human GRAS status in the USA.

